TG Therapeutics (TGTX) Reports Q3 Loss of $0.43

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. LITE
2. CRWD
3. REGN
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. ORCL

Go back to TG Therapeutics (TGTX) Reports Q3 Loss of $0.43

TG Therapeutics (TGTX) Reports Open Enrollment for Phase I Study of Novel BTK Inhibitor, TG-1701

November 13, 2018 7:36 AM EST

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the first Company sponsored Phase I study of its novel, orally available and covalently-bound Bruton Tyrosine Kinase (BTK) inhibitor, TG-1701, is open for enrollment for patients with relapsed or refractory B-cell malignancies. The first cohort evaluating TG-1701 at a dose of 100 mg once-daily has been fully enrolled, and the first patient enrolled, a patient with relapsed/refractory Mantle Cell Lymphoma (MCL), achieved a partial response (PR) at the first efficacy assessment. The remaining two... More